Biocon Wins US FDA Approval for Pebrilzo Breast Cancer Biosimilar

industry_news

Biocon Wins US FDA Approval for Pebrilzo Breast Cancer Biosimilar

Updated on Nov 17, 2026, 02:18 AM IST
Written & Edited by Harikesh VA

The U.S. Food and Drug Administration has approved the Pebrilzo (pertuzumab-qcay) injection, a biosimilar of the reference product Perjeta (pertuzumab), Biocon Limited announced, strengthening the Indian biopharmaceutical company's oncology portfolio in the United States.

The approval, announced from Bengaluru, India, and Bridgewater, New Jersey, makes PEBRILZO Biocon's fifth biosimilar cancer therapy to receive U.S. FDA approval.

A HER2-Directed Monoclonal Antibody

PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells.

 

According to the company, the FDA approval was based on a comprehensive package containing structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, which confirmed that PEBRILZO is highly similar to Perjeta with no clinically meaningful differences in quality, safety, efficacy, and immunogenicity.

The product carries boxed warnings for left ventricular dysfunction and embryo-fetal toxicity. PEBRILZO can cause subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction and congestive heart failure, and cardiac function must be evaluated prior to and during treatment.

 

Treatment must be discontinued for a confirmed clinically significant decrease in left ventricular function. Exposure to PEBRILZO can also cause embryo-fetal death and birth defects, and patients are to be advised of these risks and the need for effective contraception.

PEBRILZO is a HER2/neu receptor antagonist indicated for use in metastatic breast cancer, in combination with trastuzumab and docetaxel, for adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

 

It is also indicated for early breast cancer, in combination with trastuzumab and chemotherapy, for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, either greater than 2 cm in diameter or node positive, as part of a complete treatment regimen, and for the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.

 

The drug is contraindicated in patients with known hypersensitivity to pertuzumab or any of its excipients.

 

CEO Highlights Access and Affordability

Shreehas Tambe, CEO and Managing Director of Biocon Limited, said the approval marks another important step in the company's journey to expand access to high-quality biosimilars.

"For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families," Tambe said. "As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines."

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects in the United States

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

Launch Date Secured Through Genentech Settlement

Alongside the approval, Biocon announced a global settlement and license agreement with Genentech, securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.

 

The company noted that the approval represents an important step toward broadening treatment options for patients with HER2-positive breast cancer in the United States, subject to the anticipated commercial launch timeline.

In September, the European Medicines Agency's Committee for Medicinal Products for Human Use had given a positive opinion recommending the granting of a marketing authorization for Biocon's pertuzumab biosimilar as a 420 mg/14 mL concentrate solution for infusion under the brand name Pebrilzo for the treatment of HER2-positive breast cancer across multiple disease stages in Europe.

Portfolio of Five U.S. Oncology Biosimilars

With PEBRILZO, Biocon's U.S. oncology portfolio now totals five biosimilar therapies for cancer. The existing portfolio includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb), and Aukelso (denosumab-kyqq). PEBRILZO will join that lineup.

The company said its oncology strategy combines an established portfolio with continued development across additional treatment approaches. Its growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.

The Disease Landscape

HER2-positive breast cancer is a subtype of breast cancer characterized by HER2 protein overexpression and/or HER2 gene amplification, which drives aggressive tumor growth.

 

Approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026, according to figures cited by Biocon, and of those diagnoses, about 20 percent will be HER2-positive.

 

On a broader scale, one in eight women are expected to be diagnosed with breast cancer during her lifetime, a statistic the company cites as a reminder of the need for treatment options in this area.

About Biocon

Biocon Limited, listed on the BSE (532523) and NSE (BIOCON), describes itself as an innovation-led global biopharmaceutical company headquartered in Bengaluru, India, with a U.S. presence in Bridgewater, New Jersey.

 

The FDA approval of PEBRILZO adds to a year in which the company has advanced its pertuzumab biosimilar on both sides of the Atlantic, securing a positive CHMP opinion in Europe in September and U.S. licensure in November, with commercialization in the U.S. market scheduled to begin in the third quarter of 2028 under the terms of its Genentech agreement.

Which Chemical Mega-Projects Are Taking Shape Across the United States, And Who's Winning the Contracts?

From ethylene crackers to specialty chemical expansions, the US chemical industry is entering one of its most active capital investment cycles in a decade. But for suppliers, EPC contractors, and investors, the real challenge isn't knowing that projects exist; it's knowing which ones are moving forward, at what stage, and who holds the contracts.

 

Scattered news releases and delayed trade publications simply can't keep pace with a sector where a single cracking unit or ammonia plant decision can reshape regional supply chains overnight.

 

The Global Project Tracking (GPT) platform by Blackridge Research consolidates the entire United States chemical project pipeline into a single intelligence source, tracking developments from announcement through completion, with granular detail on owners, contractors, timelines, and capital values.

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Book a Free Demo today and see how the Global Project Tracking (GPT) platform by Blackridge Research can put the full US chemical project landscape at your fingertips.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile